NEW YORK, Oct 7 (Reuters) - The U.S. Food and Drug Administration is preparing to warn physicians about hazards with drugs that use ultrasound imaging machines to enhance the diagnosis of heart problems, the Wall Street Journal reported on its Web site on Sunday.The principal drug at issue is Definity, made by Bristol-Myers Squibb Co (BMY.N: Quote, Profile, Research), the Journal reported, adding that a second drug called Optison, from General Electric Co (GE.N: Quote, Profile, Research), is also expected to receive warnings.
